DARYL GAUGLER - 05 Jun 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
05 Jun 2023
Net transactions value
-$117,571
Form type
4
Filing time
07 Jun 2023, 21:22:07 UTC
Previous filing
02 Jun 2023
Next filing
16 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Sale $38,740 -1,000 -4.1% $38.74 23,591 05 Jun 2023 Direct F1
transaction PCRX Common Stock Sale $39,186 -1,005 -4.3% $38.99 22,586 06 Jun 2023 Direct F2
transaction PCRX Common Stock Sale $39,645 -1,047 -4.6% $37.86 21,539 07 Jun 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.